Audiologists in Newark, DE Accepting Medicare
9 Audiologists found. Showing 1 - 9
 Joanne Greene, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 774 Christiana Rd, Neuroscience Bldg Suite B4, Newark, DE 19713 Phone: 302-266-2449 Fax: 302-266-2450 |
Dr. Amanda Quaintance, AU.D Audiologist Medicare: Accepting Medicare Assignments Practice Location: 774 Christiana Rd Bldg Suiteb4, Newark, DE 19713 Phone: 302-266-2449 Fax: 302-266-2450 |
Latoya Shuler, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 630 E Chestnut Hill Rd, Newark, DE 19713 Phone: 302-454-2301 |
 Mr. James I Tyler, MA CCC/A Audiologist Medicare: Not Enrolled in Medicare Practice Location: Peoples Plaza, Suite 28, Newark, DE 19702 Phone: 302-836-9870 Fax: 302-836-4264 |
Kristine Rohrbaugh, AUD CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 4735 Ogletown Stanton Rd, Medical Arts Pavillion 2, Suite 1205, Newark, DE 19713 Phone: 302-623-4050 |
Ms. Kathleen Joan Riley, MS, CCC-A, FAAA Audiologist Medicare: Not Enrolled in Medicare Practice Location: 620 E Chestnut Hill Rd, Newark, DE 19713 Phone: 320-454-2301 Fax: 302-454-3493 |
Dr. Rebecca Dooley, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 700 Prides Xing Ste 200, Newark, DE 19713 Phone: 302-998-0300 |
Gary Marencin, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 4735 Ogletown-stanton Road, Medical Arts Pavilion 2, Suite 1205, Newark, DE 19713 Phone: 302-623-4050 Fax: 302-623-4059 |
 University Of Delaware Audiologist Medicare: Not Enrolled in Medicare Practice Location: 540 S College Ave Ste 102, Newark, DE 19713 Phone: 302-831-7100 Fax: 302-831-7101 |
News Archive
Sequential and alternating chemotherapy and radiation equally effective in larynx cancer therapy
Larynx cancer patients treated with alternating cycles of chemotherapy and radiation have similar outcomes to patients treated with chemotherapy followed by radiation, according to data from a randomized controlled trial in the January 27 online issue of the Journal of the National Cancer Institute.
Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study
BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.
Durata receives positive EMA Scientific Advice on dalbavancin clinical development plan
Durata Therapeutics today announced the Company has received positive Scientific Advice from the European Medicines Agency on the pivotal clinical development plan for dalbavancin, Durata's long-acting, intravenous lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections.
New drug screening platform identifies inhibitors of SARS-CoV-2
Researchers in the UK and the United States have developed a stem-cell-based screening platform for identifying compounds that inhibit infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent for coronavirus disease 2019 (COVID-19).
› Verified 1 days ago
Physical Therapists
Speech-Language Pathologists
Chiropractors
Occupational Therapists
Podiatrists
Optometrists
Audiologists